AMGEN INCAMGN
時価総額
$1744.4億
PER
ヒト治療薬の研究・開発・製造・販売の最大手。抗体医薬や希少疾患薬を展開。23年の大型買収、24年の新薬承認、24年に製品売上ボリューム23%増。創業から40年以上、臨床段階を含む多段階パイプライン保有。米国・欧州中心に世界展開。
| 2010年 12月31日 | 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Net income | 4,627 | 3,683 | 4,345 | 5,081 | 5,158 | 6,939 | 7,722 | 1,979 | 8,394 | 7,842 | 7,264 | 5,893 | 6,552 | 6,717 | 4,090 |
| Depreciation, amortization and other | 1,017 | 1,060 | 1,088 | 1,286 | 2,092 | 2,108 | 2,105 | 1,955 | 1,946 | 2,206 | 3,601 | 3,398 | 3,417 | 4,071 | 5,592 |
| Stock-based compensation expense | 353 | 341 | 362 | 403 | 408 | 322 | 311 | 329 | 311 | 308 | 330 | 341 | 401 | 431 | 530 |
| Deferred income taxes | - | - | - | - | - | - | - | - | -363 | -289 | -287 | -453 | -1,198 | -1,273 | -1,228 |
| Adjustments for equity method investments | - | - | - | - | - | - | - | - | - | - | - | - | -891 | -11 | 10 |
| Loss on divestiture | - | - | - | - | - | - | - | - | - | - | - | - | 567 | - | - |
| Losses (gains) on equity securities | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,565 | -159 |
| Other items, net | - | -63 | 74 | -84 | 213 | 399 | -32 | -334 | -386 | -186 | 195 | 229 | 176 | -563 | 8 |
| Trade receivables, net | 210 | 557 | -348 | 38 | -136 | 420 | 214 | 58 | 378 | 504 | 427 | 429 | 746 | 1,015 | -441 |
| Inventories | -153 | 383 | 150 | 7 | -327 | -481 | 80 | -133 | 3 | 66 | 215 | 165 | 742 | -491 | -2,532 |
| Other assets | -36 | 133 | -124 | 59 | 1 | -155 | 128 | 24 | -35 | -10 | -129 | 237 | -258 | 564 | 652 |
| Accounts payable | 142 | -95 | 161 | -184 | 405 | -12 | -44 | 424 | -143 | 164 | 45 | -69 | 154 | -402 | 312 |
| Accrued income taxes, net | -656 | -20 | 87 | -326 | -103 | 509 | -301 | 523 | -361 | -585 | -249 | -854 | -647 | -1,031 | -1,011 |
| Long-term tax liabilities | - | - | - | - | - | - | - | - | 258 | -146 | -482 | 204 | 229 | 371 | -492 |
| Accrued liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 92 |
| Accrued sales incentives and allowance | - | - | - | - | - | - | - | - | - | - | - | - | - | 935 | 1,194 |
| Other liabilities | - | 773 | 165 | 221 | 357 | 1 | 768 | 231 | 1,214 | 396 | 983 | 356 | 761 | 731 | -51 |
| Net cash provided by operating activities | 5,787 | 5,119 | 5,882 | 6,291 | 8,555 | 9,077 | 10,354 | 11,177 | 11,296 | 9,150 | 10,497 | 9,261 | 9,721 | 8,471 | 11,490 |
| Cash paid for acquisitions, net of cash acquired | - | 701 | 2,390 | 9,434 | 165 | 359 | - | 19 | -195 | 13,617 | - | 2,529 | 3,839 | 26,989 | - |
| Purchases of marketable securities | - | - | - | - | - | - | - | - | 18,741 | 9,394 | 8,477 | 8,900 | 2,587 | 1 | - |
| Proceeds from sales of marketable securities | - | - | - | - | - | - | - | - | 28,356 | 8,842 | 2,597 | 4,403 | 98 | 1,123 | - |
| Proceeds from maturities of marketable securities | 642 | 749 | 1,994 | 5,090 | 4,199 | 3,527 | 2,459 | 6,174 | 5,412 | 20,548 | 4,381 | 8,831 | 1,120 | 550 | - |
| Purchases of property, plant and equipment | 580 | 567 | 689 | 693 | 718 | 594 | 738 | 664 | 738 | 618 | 608 | 880 | 936 | 1,112 | 1,096 |
| Other | 97 | -45 | 36 | 70 | 135 | 392 | 222 | 159 | 145 | 52 | 75 | 35 | 12 | -225 | -50 |
| Net cash used in investing activities | -4,152 | -786 | -9,990 | -8,469 | -5,752 | -5,547 | -8,658 | -4,024 | 14,339 | 5,709 | -5,401 | 733 | -6,044 | -26,204 | -1,046 |
| Net proceeds from issuance of debt | 2,471 | 10,387 | 4,933 | 8,054 | 4,476 | 3,465 | 7,318 | 4,476 | - | - | 8,914 | 4,945 | 6,919 | 27,777 | - |
| Extinguishment of debt | - | - | - | - | - | - | - | - | - | - | - | - | 297 | 647 | 659 |
| Repayment of debt | - | 2,500 | 123 | 3,371 | 5,605 | 2,400 | 3,700 | 4,405 | 1,121 | 4,500 | 6,450 | 4,150 | - | 1,454 | 3,600 |
| Repurchases of common stock | 3,786 | 8,315 | 4,607 | 832 | 138 | 1,867 | 2,965 | 3,160 | 17,794 | 7,702 | 3,486 | 4,975 | 6,360 | - | 200 |
| Dividends paid | - | 500 | 1,118 | 1,415 | 1,851 | 2,396 | 2,998 | 3,365 | 3,507 | 3,509 | 3,755 | 4,013 | 4,196 | 4,556 | 4,832 |
| Other | 3 | 254 | 46 | -6 | 55 | 252 | -24 | 51 | 58 | 95 | -90 | -78 | -103 | -72 | -124 |
| Net cash (used in) provided by financing activities | -1,232 | -674 | 419 | 2,726 | -2,877 | -3,117 | -2,599 | -6,594 | -22,490 | -15,767 | -4,867 | -8,271 | -4,037 | 21,048 | -9,415 |
| Increase (decrease) in cash and cash equivalents | - | - | - | - | - | - | - | - | - | - | 229 | 1,723 | -360 | 3,315 | 1,029 |